This review discusses the evidence in support of the use of durvalumab, its pharmacology including its mechanism of action, and efficacy and tolerability as demonstrated in pivotal clinical trials.
It also provides commentary and recommendations from Associate Professor Thomas John, a medical oncologist and translational researcher at Austin Health and the Olivia Newton-John Cancer Research Institute.
Please login below to download this issue (PDF)